Lifevision healthcare	**LIFEVISION HEALTHCARE** **Plot No. 138-142, EPIP, Phase-1, Jharmajri,** **Baddi, Distt.: Solan (H.P.)-174103** **DEPARTMENT: QUALITY CONTROL** **CERTIFICATE OF ANALYSIS** **(FINISHED PRODUCT)**	Page 01 of 01

Product Name	**UZACEF – 50**		**Volume: 15 g/30 ml**
Generic Name	**Cefpodoxime Proxetil Suspension IP**		
Batch No.	LD - 0575	**A.R.No.**	QC/FP/LD - 0575
Mfg. Date	DEC. 2023	**Batch Size**	90 Ltr.
Exp. Date	MAY 2025	**Sample quantity**	12 X 15 g/30 ml
Date of Receipt	20-12-2023	**Date of release**	28-12-2023
Date of analysis	21-12-2023	**Mfg. Lic. No.**	MNB/09/804 & MB/09/805
Marketed by	**HINDUZA LIFE SCIENCE PVT. LTD.**		

S. No.	TEST	SPECIFICATION	OBSERVATION
1	Description	White powder fill in white HDPE bottles, reconstituted with water produced a yellow coloured suspension.	White powder filled in white HDPE bottles, reconstituted with water produced a yellow coloured suspension.
2	**Identification** **Cefpodoxime Proxetil IP**	**In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution.**	**In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution.**
3	pH	4.00 to 5.50	4.63
4	Weight per ml	1.00 to 1.30 g	1.1202 g
5	Average net weight	NLT 15 g/30 ml	15.0196 g/30 ml
6	Water	NMT 1.5 %	1.12 %
7	Uniformity of weight	± 9.0 %	Within the limit
8	**Assay**		

	Each 5 ml of the reconstituted suspension contains	**Claim**	**Result**	**Limit**
	Cefpodoxime Proxetil IP Equivalent to Cefpodoxime	**50 mg**	**49.955 mg (99.91 %)**	**45.0 mg to 55.0 mg (90.0 % to 110.0 %)**
	Within 7 days of reconstituted suspension			
	Cefpodoxime Proxetil IP Equivalent to Cefpodoxime	**50 mg**	**48.41 mg (96.82 %)**	**NLT 40.0 mg (NLT 80.0 %)**

Remark: The above finished product complies to as per IP & In House specification

	Analyzed by Officer-QC	**Checked by Executive-QC**	**Approved by Manager-QC**
Signature			for
Date	28-12-2023	28-12-2023	28-12-2023